453M-9
p53 (DO7) Mouse Monoclonal Antibody
登录 查看组织和合同定价。
选择尺寸
关于此项目
NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
DO7, monoclonal
Application:
IHC (p)
Species reactivity:
human
Citations:
8
Technique(s):
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
biological source
mouse
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
DO7, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (453M-94), vial of 0.5 mL concentrate (453M-95), bottle of 1.0 mL predilute (453M-97), vial of 1.0 mL concentrate (453M-96), bottle of 7.0 mL predilute (453M-98)
manufacturer/tradename
Cell Marque®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
isotype
IgG2bκ
control
colon carcinoma
shipped in
wet ice
storage temp.
2-8°C
visualization
nuclear
Gene Information
human ... TP53(7157)
Analysis Note
 IVD |  IVD |  IVD |  RUO |
General description
Anti-p53 tumor suppressor protein recognizes a 53 kDa hosphoprotein, identified as a p53 suppressor gene product. It reacts with the mutant as well as wild form of p53. Positive nuclear staining with this antibody has been shown to be a negative prognostic factor in breast carcinoma, lung carcinoma, colorectal, and urothelial carcinoma. Anti-p53 positivity has also been used to differentiate uterine serous carcinoma from endometrioid carcinoma as well as to detect intratubular germ cell neoplasia.
Other Notes
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
p53 Positive Control Slides, Product No. 453S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
法规信息
监管及禁止进口产品
此项目有
Diagnostic Immunohistochemistry: Theranostic and Genomic Applications (2002)
O Caffo et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2(9), 1591-1599 (1996-09-01)
p21 protein (p21) inhibitor of cyclin-dependent kinases is a critical downstream effector in the p53-specific pathway of growth control and can also be induced by p53-independent pathways in relation to terminal differentiation. We investigated p21 immunoreactivity in 261 breast carcinomas
Z S Zeng et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12(10), 2043-2050 (1994-10-01)
This study was performed to determine the prognostic significance of p53 gene overexpression in a homogeneous group of node-positive colorectal cancer patients. Paraffin sections from the primary tumors in 107 colorectal cancer patients who had preoperative serum carcinoembryonic antigen (CEA)
C Midulla et al.
Anticancer research, 19(5B), 4033-4037 (2000-01-11)
The different clinical evolution of breast cancer with similar pathological characteristics prompted the authors to investigate the prognostic significance of different biological markers. Seventy-one primary breast carcinoma specimens obtained by mastectomy or quadrantectomy were examined for the determination of the
D C Quinlan et al.
Cancer research, 52(17), 4828-4831 (1992-09-01)
Mutations in the gene coding for the p53 tumor suppressor protein are common in a variety of human cancers. To assess the role of a putative mutated p53 protein in human lung cancer, a monoclonal antibody recognizing it was used
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持